These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 1053885)

  • 1. Treatment of the hemophiliac with anti-VIII.
    Lewis JH; Oskins PB
    Ann N Y Acad Sci; 1975 Jan; 240():407-11. PubMed ID: 1053885
    [No Abstract]   [Full Text] [Related]  

  • 2. Advances in the treatment of hemophilia.
    Kessler CM
    Clin Adv Hematol Oncol; 2008 Mar; 6(3):184-7. PubMed ID: 18391917
    [No Abstract]   [Full Text] [Related]  

  • 3. Suppression of factor VIII antibody by combined factor VIII and cyclophosphamide.
    Nilsson IM; Hedner U; Holmberg L
    Acta Med Scand; 1974; 195(1-2):64-72. PubMed ID: 4817094
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
    Nilsson IM; Berntorp E
    Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of haemophilia.
    Lancet; 1973 Sep; 2(7830):648-9. PubMed ID: 4125623
    [No Abstract]   [Full Text] [Related]  

  • 6. Activated prothrombin concentrate for patients with factor VIII inhibitors.
    Kurczynski EM; Penner JA
    N Engl J Med; 1974 Jul; 291(4):164-7. PubMed ID: 4834485
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune tolerance for the treatment of factor VIII inhibitors--twenty years' 'bonn protocol'.
    Brackmann HH; Oldenburg J; Schwaab R
    Vox Sang; 1996; 70 Suppl 1():30-5. PubMed ID: 8869466
    [No Abstract]   [Full Text] [Related]  

  • 8. Switching haemophilia products and inhibitor risk: a United States' perspective.
    Nance D; Rodgers GM
    Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
    [No Abstract]   [Full Text] [Related]  

  • 9. Surgical care of patients with hereditary disorders of blood coagulation.
    Shulman NR
    Mod Treat; 1968 Jan; 5(1):61-83. PubMed ID: 4870180
    [No Abstract]   [Full Text] [Related]  

  • 10. Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.
    Repessé Y; Costa C; Palla R; Moshai EF; Borel-Derlon A; D'Oiron R; Rothschild C; El-Beshlawy A; Elalfy M; Ramanan V; Eshghi P; Oldenburg J; Pavlova A; Rosendaal FR; Peyvandi F; Kaveri SV; Lacroix-Desmazes S
    Haematologica; 2019 Aug; 104(8):e369-e372. PubMed ID: 30705098
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 12. Hemolysis caused by factor VIII concentrates.
    Orringer EP; Koury MJ; Blatt PM; Roberts HR
    Arch Intern Med; 1976 Sep; 136(9):1018-20. PubMed ID: 962445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of the Bethesda assay for factor VIII or IX inhibitors to improve efficiency.
    Gadarowski JJ; Czapek EE; Ontiveros JD; Pedraza JL
    Acta Haematol; 1988; 80(3):134-8. PubMed ID: 3143212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letter: Hemophilia: cyclophosphamide and factor VIII concentrate.
    Stein RS
    Ann Intern Med; 1974 Nov; 81(5):706-7. PubMed ID: 4419955
    [No Abstract]   [Full Text] [Related]  

  • 15. Acute Hepatitis E Virus infection in a hemophilic patient with acquired inhibitor during immune tolerance therapy according to modified Bonn-Malmö protocol.
    Schlabe S; van Bremen K; Goldmann G; Oldenburg J; Eis-Hübinger AM; Zeitler H; Spengler U
    Haemophilia; 2019 Mar; 25(2):e117-e120. PubMed ID: 30694010
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of hemophilia patients with inhibitors.
    Hedner U; Glazer S
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated Proplex for the haemophiliac with inhibitors. A case report.
    Hesseling PB
    S Afr Med J; 1979 Jul; 56(3):108-10. PubMed ID: 494025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors, what is the risk of treatment intensity?
    Collins PW
    J Thromb Haemost; 2007 Jul; 5(7):1380-2. PubMed ID: 17445122
    [No Abstract]   [Full Text] [Related]  

  • 19. Immune tolerance in haemophilia and the treatment of haemophiliacs with an inhibitor. Proceedings of the 2nd Workshop on Immune Tolerance. Bonn-Konigswinter, Germany, August 27-30, 1997.
    Vox Sang; 1999; 77 Suppl 1():1-100. PubMed ID: 10644229
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: Factor VIII inhibitors.
    Deykin D
    N Engl J Med; 1974 Jul; 291(4):205. PubMed ID: 4834491
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.